The recent quarterly reports, naturally, are… encouraging. Though I confess, such displays of profit always fill me with a vague sense of unease, as if some fundamental law of nature has been momentarily suspended. They speak of opportunities, of growth, of a future brimming with… chips. But let us examine this ‘growth’ with a discerning eye, shall we?
Those who bravely, or perhaps recklessly, ‘bought the dip’ are likely nursing losses that could fund a small principality. The question, then, isn’t merely can Canopy Growth recover, but should one even attempt to catch a falling… well, you get the idea.
The Danish firm, Novo Nordisk, is planning to adjust the list prices of Ozempic and Wegovy. A rather drastic adjustment, actually. The market, naturally, is in a flutter. One hears whispers of competition from Eli Lilly and their Zepbound, and frankly, a bit of a price war is rather amusing. It’s all so terribly… dramatic.
The stock’s been a bit sluggish to start the year, down around 2%. Not a catastrophe, mind you, but enough to make a few eyebrows twitch. And the company’s recent quarterly numbers were…well, let’s just say they weren’t exactly bursting with fizzy excitement. The question is: is this a wobble, or the beginning of a rather alarming tumble?
Thus, Duolingo now constitutes 8.6% of Arthedge’s reported assets under management as of December 31, 2025. A significant portion, yes, but merely a bulwark against the inevitable erosion that afflicts all such portfolios. One notes the composition of the larger holdings: Global-e Online, a speculative venture accounting for 19.2% of their assets; Shopify, at 17.2%; Amazon, a titan slowly revealing its feet of clay at 15.1%. Duolingo, at 9.3%, appears almost… hopeful, a fragile bloom in a garden of engineered desires. Crowdstrike, at 9.1%, completes this tableau of calculated bets.
The fever for space, once the exclusive domain of governments and dreamers, now clings to the markets like a persistent humidity. The numbers, of course, are impressive – six hundred and twenty-six billion dollars in 2025, a projection of a trillion by 2034 – but these are merely the skeletal remains of a deeper, more unsettling transformation. We are not simply launching satellites; we are building a second skin for the planet, a nervous system of data and surveillance. And while the optimists speak of connectivity and progress, a prudent investor understands that every revolution casts a long shadow. The scent of opportunity is often mingled with the metallic tang of risk.
But a couple of grumpy giants are interfering with this sensible behavior. These giants are called ‘macroeconomic trends’ – dreadfully boring names, aren’t they? – and they’re giving Hecla a bit of a headache. Let me explain, because these things are rarely straightforward, and grown-ups have a knack for making them extra confusing.
Apparently, this sale happened in the fourth quarter. The fourth quarter! Like it’s some profound revelation. They’re telling us this now? It’s like finding out your neighbor had a barbecue three months ago. What am I supposed to do with that information? And then they tack on this nonsense about the position’s value rising by $11.54 million. Rising! While they were selling. It’s just… contradictory. It’s like they’re trying to confuse you. And you know what? It’s working.
When things get rumblingly unpleasant in places like the Mideast – and let’s face it, they often do – people get the jitters. They start thinking, “Good heavens, what if everything goes horribly wrong?” And when they think that, they rush about buying gold. It’s a perfectly ridiculous habit, of course, but a profitable one for the gold miners. This time, they did just that. But the trouble is, gold gets bored. It doesn’t like being fussed over. So, after a brief excitement, it decides to sulk and the price slithers downwards. And when gold slithers, Newmont wobbles.
Yet, it is precisely in these moments of quietude that opportunity reveals itself. The recent decline in valuation, viewed by some as a cause for alarm, strikes me as a rather…excessive reaction. A harsh judgment upon a company that, despite its present circumspection, possesses a core strength that few can rival. It is a stock, in my estimation, unduly punished, and thus, a most attractive proposition for a patient investor.